Medical robotics company ClaraPass announced it has secured $36 million in a Series B-1 funding round, bringing its total funding to $75 million.
The round was led by Northwell Ventures, with participation from new investors Ochsner Ventures, CU Healthcare Innovation Fund and Mayo Clinic.
The New York-based company has developed SectionStar, an autonomous, AI-enabled robotic tissue sectioning and transport system, with the aim of improving operations in pathology labs through advances in tissue processing.
SectionStar is scheduled for release in the United States.
The company plans to use the funds to accelerate the commercialization of SectionStar’s products and to expand its research and development, manufacturing, service and sales capabilities.
“Together, we are building the foundation for a ‘lab of the future,’ incorporating end-to-end automation, robotics and AI into the patient tissue lifecycle,” Dr. Joaquin Garcia, chief of the division of anatomic pathology in Mayo Clinic’s Department of Laboratory Medicine and Pathology and chair of Mayo Clinic’s Digital Pathology Program, said in a statement.
ReviR Therapeutics, a biotech company using AI to develop small molecule RNA modulators for neurological diseases, secured $30 million in Series A funding, bringing its total funding to $54 million.
The round was led by Lapam Capital, with participation from 5Y Capital, Yael Capital, CDH Investments, the Charcot-Marie-Tooth Research Foundation, and XtalPi.
The California-based company plans to use the funding to further the development of its drug discovery platform, VoyageR, which targets clinical development of treatments for amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease, Huntington’s disease and other neurological disorders.
RetiSpec, The company, which offers AI-driven eye diagnostic technology for brain health, has raised $10 million in Series A funding, bringing its total funding to $17 million.
iGan Partners led the round, with participation from new investors Eli Lilly and Topcon Healthcare.
Existing investors also participated, including the Ontario Brain Institute, Gentex, Verge Healthtech Fund, the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator, University of Minnesota’s Discovery Capital, the Centre for Innovation in Aging + Brain Health, and private investors.
Lance Patton, chief commercial officer of Topcon Healthcare, will join the company’s board of directors.
LetiSpec We offer tests that help predict amyloid burden, a biomarker for Alzheimer’s disease.
The company says it expects the test, currently available only for research purposes, to one day be available for clinical use by doctors during routine examinations.
The funds will be used to accelerate the commercialization of the company’s technology.
“The completion of this Series A funding is a testament to the significant progress we’ve made and a major step towards our mission to make early and accurate detection of neurodegenerative disease markers widely available through our revolutionary AI-driven eye test,” Eliav Shaked, co-founder and CEO of Retispec, said in a statement.
“We are thrilled to welcome such a strong new investor to our existing investors, such as Gentex, who have been key contributors to our journey to date. This investment will enable us to accelerate the commercialization of AI-driven eye testing, which has the potential to transform patient outcomes and enable earlier, more accurate and equitable access to treatment.”
San Francisco-based Sound Health announced it has secured $7 million in seed funding and released SONU, an AI-enabled medical device that uses acoustic vibration energy to treat moderate to severe nasal congestion, and the SONU app.
The round was led by J4 Ventures and Moai Capital, with participation from Rhythm Venture Capital, Tau Ventures, TeleSoft Partners and TechU Ventures.
Sound Health seed investor Peter Moran will join the company’s board of directors.
SONU is FDA De Novo Classificationis a wearable device that can be used at home by individuals aged 22 years or older who suffer from nasal congestion due to rhinitis.
The AI-enabled device is an external mechanical stimulator that relieves nasal congestion by delivering acoustic vibrations to the sinus and nasal areas.
“We are pleased to announce that we have closed our seed round investment. The proceeds will be used to advance the product launch and indication pipeline of SONU Devices,” Paramesh Gopi, founder and CEO of Sound Health, said in a statement. “Sound Health’s mission is to provide personalized, intelligent wearables to help people breathe better and sleep better.”
